(all times are US Eastern)
Friday October 23, 2009 Thursday October 22, 2009
- UPDATE to "MedaSorb Technologies Draws Closer to Completion of Human Clinical Trials" as Was Previously Released on Sunday, October 18, 2009
8:59 pm - Business Wire
- Latest Clinical Experience with the FlexStent® Femoropopliteal Self Expanding Stent System in the Superficial Femoral Artery
8:00 pm - Business Wire
- KYTHERA Biopharmaceuticals Announces Two Data Presentations on Its Novel Fat Reduction Drug at ASPS Meeting
7:11 pm - Business Wire
- PDL BioPharma to Announce Third Quarter 2009 Financial Results and Hold Conference Call October 28, 2009
6:10 pm - PR Newswire
- New Disease Registries Support Comparative Effectiveness Research Priorities
6:06 pm - Business Wire
- New Study on Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII Shows Administration of Vyvanse Through Two Different Routes Demonstrated a Similar Pharmacokinetic Profile
5:42 pm - PR Newswire
- Capstone Therapeutics to Present at 4th Annual BIOCOM Investor Conference
4:51 pm - GlobeNewswire
- Intelligent InSites to Host Summit for the Advancement of Real-Time Locating and Sensing Technologies Within the Healthcare Industry
4:33 pm - Marketwire
- Depomed, Inc. to Announce Third Quarter 2009 Financial Results on October 29, 2009
4:30 pm - Business Wire
- Immunovaccine Inc. Revises Escrow Securities Schedule
4:22 pm - Marketwire
- Theravance Earns $20 Million Milestone Under Telavancin Collaboration Agreement
4:20 pm - Marketwire
- EMD Chemicals Expands Multi-Analyte Portfolio Via Collaboration with MitoSciences to Develop and Distribute Assays for Drug Toxicity and Mitochondrial Bioactivity
4:16 pm - Business Wire
- Seattle Genetics Highlights Pipeline Progress and Reports Third Quarter 2009 Financial Results
4:10 pm - Business Wire
- Agilent Technologies Appoints Ambry Genetics as First Certified Service Provider for Agilent's Target Enrichment System for Next-Gen Sequencing
4:09 pm - PR Newswire
- Anadys Pharmaceuticals to Report Third Quarter 2009 Financial Results
4:05 pm - PR Newswire
- Orthovita Announces 2009 Third Quarter Sales
4:01 pm - Business Wire
- Gen-Probe Completes Acquisition of Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases
4:01 pm - PR Newswire
- Repligen Licenses Potential Treatment for Spinal Muscular Atrophy
4:00 pm - PR Newswire
- Dynavax Announces Third Quarter 2009 Financial Results
4:00 pm - Business Wire
- TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients
3:45 pm - PR Newswire
- NeurAxon, Inc. to Present at Upcoming Investor and Business Development Conferences
3:04 pm - Business Wire
- Affygility Solutions to Provide Global Harmonization System (GHS) - Strategies for Implementation
3:03 pm - Business Wire
- Nu Skin Announces Research Agreements With Stanford University and LifeGen Technologies
3:00 pm - PR Newswire
- Imaging Crucial for "Personalized Medicine" to Succeed, Says Report
2:58 pm - Marketwire
- MMR Information Systems Hosts Open House for Physicians With Kodak in Attendance November 4-5 at Fall Health IT Summit in Beverly Hills
2:57 pm - Marketwire
- BioTime, Inc. Announces Approval For NYSE Amex Listing
2:57 pm - Business Wire
- Nutra Pharma Announces Publication of Research Report by Cohen Independent Research Group
2:48 pm - Business Wire
- elliquence, LLC. and Bonovo Orthopedics, Inc. Announce a Partnership to Bring Products to China
2:33 pm - Business Wire
- Systagenix Unveils SILVERCEL* Non-Adherent Silver Hydro Alginate Dressing
2:21 pm - PR Newswire
- Synovis Life Technologies Receives CE Mark Approval for the Use of Veritas® Collagen Matrix in Hernia Repair and Breast Reconstruction
2:15 pm - Business Wire
- Proposal to Place Biomass, Biofuels Under CO2 Emission Cap is Based on Flawed Logic, BIO Says
2:10 pm - Business Wire
- Research and Markets: 2009 CRO Quality Benchmarking Study - CRO Selection for Biotechnology Companies
1:18 pm - Business Wire
- Nutri5(R) and Brain Health related to treatment of menopausal symptoms
12:59 pm - Marketwire
- NexGenix Pharmaceuticals Awarded Phase I Grant from the National Institute of Neurological Disorders and Stroke (NINDS) Small Business Innovation Research Program (SBIR) for the Development of Novel Small Molecule Hsp90 Therapeutics to Trea
12:58 pm - PR Newswire
- BAPTIST HEALTH Now Offers Unique Alternative to Total Hip Replacement
12:57 pm - Marketwire
- HearAtLast CEO Sets Goal to Become Canada's Largest Chain of Hearing Devices
12:54 pm - Marketwire
- Biotech Finances - The Unique Resource for Finance and Business Intelligence in the World of Biotech
12:33 pm - Business Wire
- RainDance Extends Sequence Enrichment Solution Capabilities With Methyl-Seq and Ultra-Deep Resequencing Applications
12:32 pm - Business Wire
- Acrongenomics maintains its stake in Molecular Vision
12:32 pm - Business Wire
|
|